4-Aminoisoindoline-1,3-Dione Combination Therapy for Drug-Resistant Leukemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, particularly for hematological malignancies, face significant drawbacks such as toxicity, severe side effects, and multidrug resistance, making them ineffective against resistant tumor cells.
Innovation Solution
Combining (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (Compound 1) with second active agents like HDAC inhibitors, BCL2 inhibitors, and others, to treat, prevent, or manage hematological malignancies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapeutic agents are used to treat hematological malignancies, then tumor cells can be eradicated, but drug resistance develops making treatment ineffective
Solution Approach 1:
The patent combines Compound 1 with second active agents (such as HDAC inhibitors, BCL2 inhibitors, BTK inhibitors, and other chemotherapy agents) to create combination therapies that overcome drug resistance. The synergistic interaction between Compound 1 and the second active agent restores sensitivity in resistant tumor cells, allowing effective treatment of hematological malignancies that have developed resistance to single-agent chemotherapy.
2Reliability
If chemotherapeutic agents are administered to eradicate neoplastic cells, then cancer progression is halted, but severe side effects including bone marrow depression and immunosuppression occur
Solution Approach 1:
The patent utilizes Compound 1, a BCL-2 homologue 3 (BH3) mimetic compound, which has a different mechanism of action compared to traditional chemotherapeutic agents. This parameter change in the therapeutic approach allows for effective cancer cell eradication through induction of apoptosis via mitochondrial pathways, potentially reducing the severity of side effects associated with conventional chemotherapy while maintaining treatment efficacy.
3Adaptability or versatility
If multiple chemotherapeutic agents are used in combination, then treatment coverage is expanded, but toxicity and side effects are amplified
Solution Approach 1:
The patent positions Compound 1 as an intermediary agent that works synergistically with second active agents to achieve enhanced treatment coverage. Rather than simply adding more chemotherapeutic agents which would amplify toxicity, Compound 1 acts as a mediator that restores sensitivity to existing therapies and enhances their efficacy through synergistic interactions, thereby expanding treatment coverage without proportionally increasing toxicity.
Data Source
Figure 1
Figure 2
Figure 2
AI summary
Provided herein are methods of using (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3- morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, in combination with a second active agent for treating, preventing or managing hematological malignancies. The second active agent is one or more of an HDAC inhibitor, a BCL2 inhibitor, a BTK inhibitor, an mTOR inhibitor, a PI3K inhibitor, a PKCĪ² inhibitor, a SYK inhibitor, a JAK2 inhibitor, an Aurora kinase inhibitor, an EZH2 inhibitor, a BET inhibitor, a hypomethylating agent, a DOT1L inhibitor, a HAT inhibitor, a WDR5 inhibitor, a DNMT1 inhibitor, an LSD-1 inhibitor, a G9A inhibitor, a PRMT5 inhibitor, a BRD inhibitor, a SUV420H1/H2 inhibitor, a CARM1 inhibitor, a PLK1 inhibitor, an NEK2 inhibitor, an MEK inhibitor, a PHF19 inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an XPO1 inhibitor, a BIRC5 inhibitor, or a chemotherapy.